A Randomized Comparison of the Endeavor Zotarolimus-Eluting Stent Versus the TAXUS Paclitaxel-Eluting Stent in De Novo Native Coronary Lesions: 12-Month Outcomes From the ENDEAVOR IV Trial

The ENDEAVOR IV (Randomized Comparison of Zotarolimus-Eluting and Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease) trial evaluated the safety and efficacy of the zotarolimus-eluting stent (ZES) compared with the paclitaxel-eluting stent (PES). First-generation drug-eluting stents...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American College of Cardiology 2010-02, Vol.55 (6), p.543-554
Hauptverfasser:	LEON, Martin B, MAURI, Laura, BALL, Michael W, CAPUTO, Ronald P, JAIN, Ash, TOLLESON, Thaddeus R, REEN, Bernard M, KIRTANE, Ajay J, FITZGERALD, Peter J, THOMPSON, Kweli, KANDZARI, David E, POPMA, Jeffrey J, CUTLIP, Donald E, NIKOLSKY, Eugenia, O'SHAUGHNESSY, Charles, OVERLIE, Paul A, MCLAURIN, Brent T, SOLOMON, Stuart L, DOUGLAS, John S
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Biological and medical sciences Cardiology Cardiology. Vascular system Clinical outcomes Coronary Artery Disease - drug therapy Coronary heart disease Drug therapy Drug-Eluting Stents Female Heart Heart attacks Humans Immunosuppressive Agents - administration & dosage Male Medical sciences Middle Aged Paclitaxel - administration & dosage Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) Single-Blind Method Sirolimus - administration & dosage Sirolimus - analogs & derivatives Stents Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!